CD274 and cholangiocarcinoma: Among them, related hotspots such as tumor mutational burden, microenvironment, PD-L1 expression, nivolumab, combination therapy, targeted therapy, immune cells, and macrophages have been the primary areas of interest in CCA immunotherapy since 2019 (Supplementary Figure S4).